Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy

Authors :: Fred Saad
Arturo Molina
Thian Kheoh
Michael Marberger
C. M. Haqq
Karim Fizazi
Kim N. Chi
Peter F.A. Mulders
Jinhui Li
Celestia S. Higano
Source :: European Urology, 65, 875-83, European Urology, 65, 5, pp. 875-83
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.
Abstract: Item does not contain fulltext BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is a disease that primarily affects older men. Abiraterone acetate (AA), a selective androgen biosynthesis inhibitor, in combination with low-dose prednisone (P) improved overall survival (OS) in a randomised trial in mCRPC progressing after docetaxel versus placebo (PL) plus P. OBJECTIVE: To examine the efficacy and safety of AA plus P versus PL plus P in subgroups of elderly (aged >/=75 yr) (n=331) and younger patients (

Tools